Two new RSV vaccine candidates, made by Pfizer and GlaxoSmithKline, could become the world’s first approved vaccines against the common virus respiratory syncytial virus (RSV). The FDA, which typically follows the committee’s recommendations, is expected to decide on approval in May, ahead of the typical RSV price hike in winter.
